Small Molecules in Oncology
Small Molecules in Oncology
edited by Uwe M. Martens.
- 2nd ed. 2014
- Berlin, Heidelberg Springer 2014
- 1 recurso en línea (XVI, 417 páginas) 46 ilustraciones, 26 ilustraciones en color
- Recent Results in Cancer Research 201 0080-0015 .
Imatinib Mesylate -- Erlotinib -- Axitinib (AG-013736) -- Lapatinib -- Sorafenib -- Sunitinib -- Dasatinib -- Nilotinib -- Bosutinib -- Decitabine -- Azacytidine/Azacitidine -- Bortezomib -- Temsirolimus -- Danusertib -- Vismodegib -- Everolimus -- Vemurafenib -- Vandetanib -- Trametinib -- Dabrafenib -- Ponatinib -- Regorafenib -- Cabozantinib -- Revlimid -- Ibrutinib -- Qizartinib -- Ruxolitinib -- Carfilzomib -- Afitinib.
Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.
9783642544903
10.1007/978-3-642-54490-3 doi
Cáncer--Aspectos genéticos
Oncología
RC268.4 / 2014 EB
Imatinib Mesylate -- Erlotinib -- Axitinib (AG-013736) -- Lapatinib -- Sorafenib -- Sunitinib -- Dasatinib -- Nilotinib -- Bosutinib -- Decitabine -- Azacytidine/Azacitidine -- Bortezomib -- Temsirolimus -- Danusertib -- Vismodegib -- Everolimus -- Vemurafenib -- Vandetanib -- Trametinib -- Dabrafenib -- Ponatinib -- Regorafenib -- Cabozantinib -- Revlimid -- Ibrutinib -- Qizartinib -- Ruxolitinib -- Carfilzomib -- Afitinib.
Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.
9783642544903
10.1007/978-3-642-54490-3 doi
Cáncer--Aspectos genéticos
Oncología
RC268.4 / 2014 EB